Matthew Harlin, MD, MS

Pharmacokinetic Profile of Multiple-Dose Aripiprazole 2-Month Ready-to-Use 960 mg Versus Aripiprazole Once-Monthly 400 mg in Adults With Schizophrenia or Bipolar I Disorder

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months, inten...

Matthew Harlin , MD, MS;

Sarah Ramsden ;

01/19/2023

Development of a Population Pharmacokinetic Model to Describe the Pharmacokinetics of Aripiprazole 2-Month Ready-to-Use, a New Long-Acting Injectable Formulation for Administration Once Every 2 Months

Aripiprazole 2-month ready-to-use (Ari 2MRTU) is a novel long-acting injectable formulation of aripiprazole monohydrate for gluteal intramuscular administration once every 2 months. A pre...

Matthew Harlin , MD, MS;

10/26/2023

Pharmacokinetic Simulations of Aripiprazole 2-Month Ready-To-Use Long-Acting Injectable to Inform Administration in Adult Patients With Schizophrenia or Bipolar-I Disorder

Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a novel long-acting injectable formulation of aripiprazole for gluteal administration once every 2 months. Simulations conducte...

Matthew Harlin , MD, MS;

10/26/2023